News

This segment of Eichenfield’s interview features a discussion about the recent announcement of a J-Code for the molluscum contagiosum treatment cantharidin.

Our January 2024 sleep month in review includes studies regarding periodic limb movements to link to cardiovascular disease and death, sleep apnea serving as a risk factor for uncontrolled, severe asthma, and more.

Tirzepatide, a dual GLP-1/GIP agonist approved for diabetes and obesity, was associated with significant blood pressure reductions in an analysis of the SURMOUNT-1 trial.

The biosimilars month in review explores the efficacy and safety of biosimilars in treating uveitis, highlights the FDA’s acceptance of a biologics license application for an ustekinumab biosimilar, and emphasizes the safety and accessibility benefits of biosimilars in rheumatic conditions.

Data from the phase 2 METforMIN trial do not support the use of oral metformin for reducing the progression of geographic atrophy.

In this interview, Eichenfield discussed the recent pooled analysis from two phase 3 studies looking at once-daily, topical roflumilast for patients 6 and older with eczema.

In an interview with HCPLive, Daniel Greer, PharmD discussed his team’s study on how antipsychotic injections were linked to a greater reduction in 30-day rehospitalizations than oral medication.

The editorial team’s monthly recap of the top news in hepatology features research emphasizing women’s health in liver disease, a look at some less-recognized health benefits associated with achieving SVR, and promising approaches for preventing and treating hepatic conditions.

Vision screening rates for amblyopia showed substantial increase after photoscreening expansion, but patients who were Asian, Black, and Hispanic were less likely to be screened.

This announcement is part of the overall evaluation period for the treatment, as the PDUFA target action date for pz-cel remains May 2024.

Although a new study found antidepressants from SSRI or SNRI did not increase the risk of hemorrhagic stroke or other serious bleeding in ischemic stroke survivors, the risk increased when taking antidepressants of other classes and anti-platelet medications.

The FDA approval of Edwards Lifesciences EVOQUE tricuspid valve replacement system for treatment of symptomatic severe tricuspid regurgitation is the first of its kind for a transcatheter therapy.

Our January 2024 psychiatry month in review includes studies finding associations with depression, anxiety, and anorexia nervosa, as well as a phase 3 study looking into long-term safety of olanzapine, samidorphan.

Study results called attention to the negative impact of living in a rural residence and a highly dependent neighborhood on HCV screening by 2 years of age in children born to HCV RNA positive mothers.

January’s Dermatology Month in Review features 2 major FDA decisions, positive results on a new assessment tool, an evaluation of climate change’s impact on eczema, and more.

Study presented at ISC 2024 suggests Black women with hypertension before age 35 face a 3-fold increase in risk of stroke while hypertension before 45 linked to doubling in stroke risk.

Obesity was linked to an increased risk of focal segmental glomerulosclerosis and hypertensive nephropathy, with further analysis revealing its impact on the risk of developing end-stage kidney disease.

Faricimab showed sustained vision improvements and retinal drying up to 72 weeks for both branch and central RVO in the phase 3 BALATON and COMINO studies.

This new warning for consumers cautions against use of Rebright, South Moon, or FivFivGo eye drops as a result of potential eye infection risks.

A systematic review suggests practitioners using enhanced empathy improves patient satisfaction, but research is hindered by inadequate reporting and heterogeneity.

Each month, our editorial staff compiles a recap of the top news in ophthalmology. Our January 2024 month-in-review features crucial research on social determinants of health, updates on the latest ophthalmic pipeline developments, and a look at how the local environment affects eye health.

These data highlight the severe economic burden faced by patients with vitiligo compared to that of the general population, including mental health-related costs.

In the wake of Vera Therapeutics announcing positive 72-week data from the phase 2b ORIGIN trial, we sat down with lead investigator Richard Lafayette, MD, to learn more about how he interprets the latest data from the atacicept program in IgA nephropathy.

Following the January 25, 2024 approval of dupilumab for eosinophilic esophagitis in patients 1-11 years of age, a trio of pediatric gastroenterologists shares their thoughts on the new indication, their anticipated priority of use, and potential hurdles to optimal treatment uptake.

This analysis of current testing patterns in the US suggests a need for future studies to explore the rationale used to determine such testing decisions.

In a survey, 1 in 6 cisgender men and women reported unmet mental health needs at their latest visit with a healthcare professional. Mental health needs for other gender identities ranged from 1 in 5 and 1 in 4.

Our January 2024 Month in Review spotlights the FDA approval of a new indication of dupilumab (Dupixent) for pediatric eosinophilic esophagitis, new clinical trial data, and research about the prevention and management of IBD.

Even when cholesterol levels were only moderately elevated, familial hypercholesterolemia variants were associated with greater cardiovascular risk.